Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)
Organizer(s) Christian Klein, Mark S. Cragg and Germaine Fuh
April 7—11, 2019
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Dec 11, 2018
Abstract Deadline: Jan 9, 2019
Scholarship Deadline: Dec 11, 2018
Discounted Registration Deadline: Feb 6, 2019
Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG and Roche
Summary of Meeting:
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
View Scholarships/Awards
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
MONDAY, APRIL 8
TUESDAY, APRIL 9
WEDNESDAY, APRIL 10
THURSDAY, APRIL 11
FRIDAY, APRIL 12
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.
*
Christian Klein,
Roche, Switzerland
George D. Yancopoulos,
Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application
Target Identification and Developing Antibodies for Clinical Application
Jennifer R. Cochran,
Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics
Emerging Strategies for Developing Next-Generation Protein Therapeutics
Coffee Break
09:50—11:45
Mechanisms of Action for Depleting Antibodies
Meeting has ended...abstracts no longer viewable online.
*
Janine Schuurman,
Genmab B.V., Netherlands
Mark S. Cragg,
University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity
Targeting B Cells with Antibodies: From Oncology to Autoimmunity
Falk Nimmerjahn,
Universitätsklinikum Erlangen, Germany
The Where, When, and How: Organ Specific Pathways of Cytotoxic IgG Activity
The Where, When, and How: Organ Specific Pathways of Cytotoxic IgG Activity
Annalee W. Nguyen,
University of Texas at Austin, USA
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment
Polina Weitzenfeld,
Rockefeller University, USA
Short Talk: Antibody Targeting of Carbohydrate-Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance
Short Talk: Antibody Targeting of Carbohydrate-Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance
Michael Schmidt,
Compass Therapeutics, USA
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain-Based Bispecific Antibodies
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain-Based Bispecific Antibodies
14:30—16:30
Workshop 1: Engineering (Bispecific) Antibodies
*
Christian Klein,
Roche, Switzerland
Starlynn Clarke,
TeneoBio Inc., USA
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
Lynn A. Kamen,
Genentech, Inc., USA
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects
Jason Lajoie,
Compass Therapeutics, USA
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies
Ahlam Qerqez,
University of Texas at Austin, USA
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display
Diana Darowski,
Roche Gylcart AG, Switzerland
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)
Koen Wagner,
AIMM Therapeutics, Netherlands
AT1413 T-Cell Engager Activity Is Determined by T-Cell Engager Format Valency
AT1413 T-Cell Engager Activity Is Determined by T-Cell Engager Format Valency
Phillip Liu,
Sound Biologics, USA
Development of MabPair Technology, a Novel Platform for Producing Bifunctional Antibody Products
Development of MabPair Technology, a Novel Platform for Producing Bifunctional Antibody Products
Brandy R. White,
California State University, Fresno, USA
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer
17:00—19:00
Antibody Engineering
Meeting has ended...abstracts no longer viewable online.
*
James A. Ernst,
Genentech, Inc., USA
Janine Schuurman,
Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats Inspired by Nature
Engineering Non-Classical Antibody Formats Inspired by Nature
Feng Wang,
Chinese Academy of Sciences, China
A Tumor Targeted Immune Checkpoint Blocker
A Tumor Targeted Immune Checkpoint Blocker
Germaine Fuh,
23andMe, USA
Engineering Antibody Specificity and Stability Using Deep Sequencing
Engineering Antibody Specificity and Stability Using Deep Sequencing
Aliza Borenstein-Katz,
Weizmann Institute, Israel
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker
Chia Yin Lee,
Singapore Immunology Network, Singapore
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Bispecific and Engineered Antibodies for Cancer Immunotherapy
Meeting has ended...abstracts no longer viewable online.
*
Andreas G. Plückthun,
University of Zürich, Switzerland
Nai-Kong V. Cheung,
Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies
Christian Klein,
Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy
Coffee Break
John R. Desjarlais,
Xencor, Inc., USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation
Bispecific Antibodies for T Cell Recruitment and T Cell Activation
Yvonne Y. Chen,
University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors
Engineering Next-Generation Chimeric Antigen Receptors
Udaya S Rangaswamy,
Teneobio, USA
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell-Mediated Killing of Tumor Cells with Minimal Cytokine Release
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell-Mediated Killing of Tumor Cells with Minimal Cytokine Release
Lina Bartels,
AIMM Therapeutics & Amsterdam University Medical Center, Netherlands
Short Talk: A T-Cell Engager Based on a Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo without Affecting Normal Hematopoietic Cells
Short Talk: A T-Cell Engager Based on a Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo without Affecting Normal Hematopoietic Cells
Chad May,
Maverick Therapeutics, USA
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice
17:00—19:00
Antibodies for Infectious Diseases
Meeting has ended...abstracts no longer viewable online.
*
Christoph Rader,
The Scripps Research Institute, USA
David D. Ho,
Aaron Diamond AIDS Research Center, USA
A Bispecific Antibody, 10E8.4/iMab, for HIV Therapy and Prevention
A Bispecific Antibody, 10E8.4/iMab, for HIV Therapy and Prevention
JoAnn A. Suzich,
AstraZeneca, USA
Antibodies for the Prevention and Treatment of Viral Infections
Antibodies for the Prevention and Treatment of Viral Infections
Kartik Chandran,
Albert Einstein College of Medicine, USA
Development of Engineered and Natural Antibodies as Anti-Ebola Therapeutics
Development of Engineered and Natural Antibodies as Anti-Ebola Therapeutics
Sisi Shan,
Tsinghua University, China
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus
Anna Zumsteg,
Regeneron Pharmaceuticals, USA
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Antibody Drug Conjugates
Meeting has ended...abstracts no longer viewable online.
*
Germaine Fuh,
23andMe, USA
Ronit Mazor,
MedImmune, USA
Immunogenicity of Recombinant Immunotoxins and Approaches to Mitigate It
Immunogenicity of Recombinant Immunotoxins and Approaches to Mitigate It
Kerry Culm-Merdek,
ImmunoGen, USA
Optimizing the Activity of Antibody Drug Conjugates
Optimizing the Activity of Antibody Drug Conjugates
Coffee Break
John M. Lambert,
, USA
Site-Specific Conjugation in ADC Design: Panacea or Hype? Lessons from a Case Study with a Maytansinoid Conjugate
Site-Specific Conjugation in ADC Design: Panacea or Hype? Lessons from a Case Study with a Maytansinoid Conjugate
W. Michael Kavanaugh,
Cytomx Therapeutics, USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies
Armine Matevossian,
Novartis Institutes for BioMedical Research, USA
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug
Bradley Pearse,
Magenta Therapeutics, USA
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Brian H. Santich,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: Self-Assembling and Disssembling (SADA) Bispecific Antibodies (BsAb) for 2-Step Pretargeted RadioImmunotherapy (PRIT)
Short Talk: Self-Assembling and Disssembling (SADA) Bispecific Antibodies (BsAb) for 2-Step Pretargeted RadioImmunotherapy (PRIT)
17:00—19:00
Delivering Antibodies into the Brain
Meeting has ended...abstracts no longer viewable online.
*
Jennifer R. Cochran,
Stanford University, USA
Joy Yu Zuchero,
Denali Therapeutics Inc, USA
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach
Per-Ola Freskgard,
Roche Innovation Center Basel, Switzerland
Crossing the Blood-Brain Barrier with Antibodies to Access Brain Targets
Crossing the Blood-Brain Barrier with Antibodies to Access Brain Targets
Allan Jensen,
Lundbeck, Denmark
Antibody-Based Therapies for Neurodegenerative Diseases
Antibody-Based Therapies for Neurodegenerative Diseases
Mathieu Oosterlaken,
Institut de Génomique Fonctionelle, France
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain
Chiara Figazzolo,
University of Cambridge, UK
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Bispecific Antibodies and Antibody Like Molecules
Meeting has ended...abstracts no longer viewable online.
*
Christian Klein,
Roche, Switzerland
James A. Ernst,
Genentech, Inc., USA
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH
Coffee Break
Andreas G. Plückthun,
University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells
Engineering DARPins for Delivery into Cells
Krzysztof Masternak,
NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer
Bispecific CD47 Antibodies for Treatment of Cancer
Peter J. Hudson,
Avipep Pty Ltd, Australia
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases
Leandrew A. Dailey,
Albert Einstein College of Medicine, USA
Short Talk: Engineering Next-Generation Bispecific Antibodies against Filoviruses
Short Talk: Engineering Next-Generation Bispecific Antibodies against Filoviruses
14:30—16:30
Workshop 2: Antibodies for Immunological Applications
*
Mark S. Cragg,
University of Southampton, UK
Nicole Piché-Nicholas,
Pfizer, USA
Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics
Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics
Trevor RF Smith,
Inovio Pharmaceuticals, USA
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)
Olivia Vergnolle,
Albert Einstein College of Medicine, USA
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement
Masahiro Yasunaga,
National Cancer Center, Japan
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging
Henry Wilson,
The Scripps Research Institute, USA
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries
Gregory Mann,
École Polytechnique Fédérale de Lausanne, Switzerland
Using Monobodies to Target Cytoplasmic Oncoproteins
Using Monobodies to Target Cytoplasmic Oncoproteins
17:00—18:45
Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy
Meeting has ended...abstracts no longer viewable online.
*
Mark S. Cragg,
University of Southampton, UK
Mikael C. I. Karlsson,
Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy
Anti-Marco Antibodies in Tumor Immunotherapy
Sean Hua Lim,
University of Southampton, UK
Optimizing Anti-Tumor Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists
Optimizing Anti-Tumor Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists
Sapna Yadavilli,
GlaxoSmithKline, USA
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody
Wen Jie Chin,
Agency for Science, Technology and Research, Singapore
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
